Revisiting the link between COVID-19 incidence and infection fatality rate during the first pandemic wave
- PMID: 40325150
- PMCID: PMC12053613
- DOI: 10.1038/s41598-025-99078-6
Revisiting the link between COVID-19 incidence and infection fatality rate during the first pandemic wave
Abstract
Several studies found an association between COVID-19 incidence, cumulated over the first pandemic wave, and the risk of death for infected individuals. They attributed this association to hospital overload. We studied this association across the French departments using 82,467 serological samples and a hierarchical Bayesian model with spatial smoothing. In high-incidence areas, we hypothesized that hospital overload would increase infection fatality rate (IFR) without increasing infection hospitalization rate (IHR). The analyses were adjusted for intensive care beds per capita, age of the population, and diabetes prevalence (as a surrogate for obesity). We found that increasing departmental incidence from 3 to 9% rose IFR from 0.42 to 1.14% (difference 0.72%, 95% CI 0.49-1.01%), and IHR from 1.66 to 3.61% (difference 1.94%, 95% CI 1.18-2.80%). An increase in incidence from 6 to 12% in people under 60 was associated with an increased proportion of people over 60 among those infected, from 11.6 to 17.4% (difference 5.8%, 95% CI 2.9-8.8%). Higher incidence increased the risk of death for infected individuals and their risk of hospitalization by the same magnitude. These findings could be explained by a higher age among infected individuals in high-incidence areas, rather by than hospital overload.
Keywords: Bayesian statistics; COVID-19; Causal graph; Hierarchical modeling; Hospital overload; Spatial modeling.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: Ethical approval and written or electronic informed consent were obtained from each participant before enrollment in the original cohort. The SAPRIS-SERO study was approved by the Sud-Mediterranée III ethics committee (approval 20.04.22.74247) and electronic informed consent was obtained from all participants for dried blood spot testing. The study was registered (#NCT04392388). All methods were performed in accordance with the relevant guidelines and regulations. Consent for publication: Participants can not be identified on the basis of this article.
Figures





References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical